731 related articles for article (PubMed ID: 18303491)
1. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
Stacy M; Galbreath A
Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
[TBL] [Abstract][Full Text] [Related]
2. [Management of Parkinson's disease in 2009].
Maertens de Noordhout A
Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
[TBL] [Abstract][Full Text] [Related]
3. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
4. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
6. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Tse W
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
[TBL] [Abstract][Full Text] [Related]
7. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Olanow CW; Obeso JA; Stocchi F
Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
[TBL] [Abstract][Full Text] [Related]
8. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Facca A; Sanchez-Ramos J
Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
[No Abstract] [Full Text] [Related]
9. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
10. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
11. The management approaches to dyskinesia vary from country to country.
Woitalla D; Mueller T; Russ H; Hock K; Haeger DA
Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of L-dopa induced dyskinesia].
Kuno S
Nihon Rinsho; 2000 Oct; 58(10):2110-4. PubMed ID: 11068456
[No Abstract] [Full Text] [Related]
13. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
14. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
15. Are there clinically significant differences between dopamine agonists.
Stocchi F; Vacca L; Onofrj M
Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
[No Abstract] [Full Text] [Related]
16. [Current preclinical findings on substances against Parkinson's disease].
Gerlach M; Riederer P
Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
[TBL] [Abstract][Full Text] [Related]
17. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
18. Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Jann MW
Am J Manag Care; 2011 Oct; 17 Suppl 12():S315-21. PubMed ID: 22087552
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
Bhidayasiri R; Ling H
J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
[TBL] [Abstract][Full Text] [Related]
20. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
